| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FEO; OFE; ODFR; OSTS; PDB2; RANK; CD265; OPTB7; TRANCER; LOH18CR1 |
| WB Predicted band size | 66 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human TNFRSF11A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TNFRSF11A(RANK)抗体的3篇代表性文献的简要整理：
---
1. **标题**：*Osteoprotegerin Ligand is a Cytokine that Regulates Osteoclast Differentiation and Activation*
**作者**：Lacey, D.L., et al.
**摘要**：该研究首次阐明了RANK配体(RANKL)通过结合TNFRSF11A(RANK)受体激活破骨细胞分化的机制，并利用抗RANK抗体阻断该通路，证实其在骨代谢调控中的关键作用，为骨质疏松治疗提供了理论依据。
2. **标题**：*RANK is Essential for Osteoclast and Lymph Node Development*
**作者**：Kong, Y.Y., et al.
**摘要**：通过基因敲除小鼠模型，研究发现TNFRSF11A(RANK)缺失导致破骨细胞发育缺陷和淋巴结形成异常，进一步利用特异性抗体验证了RANK在骨重塑和免疫系统中的双重功能。
3. **标题**：*Targeting RANK Signaling in Breast Cancer-Induced Osteolytic Metastasis*
**作者**：Jones, D.H., et al.
**摘要**：该文献报道了抗TNFRSF11A抗体在乳腺癌骨转移模型中的应用，显示其通过抑制RANK信号通路显著减少骨破坏，提示抗体在癌症骨转移治疗中的潜在价值。
---
注：以上文献为领域内经典研究，主要涵盖TNFRSF11A抗体的机制探索及疾病治疗应用。如需近年研究或实验抗体开发相关文献，建议通过PubMed/Google Scholar检索最新关键词(如“anti-RANK antibody therapeutic”)。
TNFRSF11A (tumor necrosis factor receptor superfamily member 11A), also known as RANK (receptor activator of nuclear factor kappa-B), is a transmembrane protein encoded by the TNFRSF11A gene. It plays a critical role in regulating osteoclast differentiation, activation, and survival by binding to its ligand RANKL (RANK ligand). This interaction is essential for bone remodeling and immune system modulation. Dysregulation of RANK/RANKL signaling is implicated in pathological conditions such as osteoporosis, rheumatoid arthritis, and bone metastases in cancers.
Antibodies targeting TNFRSF11A are valuable tools for research and therapeutic applications. In research, anti-TNFRSF11A antibodies are used to study receptor expression, signaling pathways, and cellular responses in bone biology, immunology, and cancer. They enable techniques like immunohistochemistry, flow cytometry, and Western blotting to visualize or quantify RANK expression in tissues or cells. Therapeutically, blocking RANK signaling with monoclonal antibodies (e.g., denosumab, which targets RANKL) has been approved to treat bone loss disorders and prevent skeletal-related events in malignancies. Direct anti-TNFRSF11A antibodies are less common but are explored for their potential to modulate osteoclast activity or inflammatory responses. Challenges include balancing efficacy with off-target effects, as RANK signaling also impacts immune cells. Ongoing studies aim to refine antibody specificity and optimize clinical applications in bone diseases and cancer immunotherapy.
×
